harmaline has been researched along with 1-methyl-4-phenylpyridinium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cobuzzi, RJ; Collins, MA; Neafsey, EJ | 1 |
| Beach, JW; Collins, MA; Gearhart, DA; Hwang, YI; Neafsey, EJ; Schwarz, J; Storch, A | 1 |
2 other study(ies) available for harmaline and 1-methyl-4-phenylpyridinium
| Article | Year |
|---|---|
Differential cytotoxicities of N-methyl-beta-carbolinium analogues of MPP+ in PC12 cells: insights into potential neurotoxicants in Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cations; Cell Death; Culture Media; Energy Metabolism; Harmaline; Kinetics; L-Lactate Dehydrogenase; Methylation; Molecular Structure; Parkinson Disease; PC12 Cells; Rats | 1994 |
Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Cell Line; Cell Survival; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Harmaline; Harmine; Humans; Inhibitory Concentration 50; Kidney; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Methylation; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperazines | 2004 |